BiologicalDrug
C1 esterase inhibitor (human) clinical trials
Also written CINRYZE and Berinert.
Keep track of what changes. Save the C1 esterase inhibitor (human) studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
18 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 6
Shire (7) · Pharming Technologies B.V. (4) · Cedars-Sinai Medical Center (1) · Technical University of Munich (1) · GCS Ramsay Santé pour l'Enseignement et la Recherche (1) · CSL Behring (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Leiden University Medical Center (1)
Often tested with
Tested in the same studies.
Conestat alfa (4) · Complement C1 Inhibitor Protein (4) · Hyaluronidase (human recombinant) (2) · Icatibant (1) · CSL830 (1)
Studies
Open first, then newest update. How each study uses C1 esterase inhibitor (human) is read from its arms, and is right about nine times in ten.
Testing it · 18
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)RecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06919003Written as Berinert
- Berinert (C1INH) vs Placebo for DGF/IRICompletedPhase 1/2Cedars-Sinai Medical CenterNCT04696146Written as Berinert
- Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced AngioedemaCompletedPhase 3Technical University of MunichNCT01843530Written as Berinert
- Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).CompletedPhase 2GCS Ramsay Santé pour l'Enseignement et la RechercheNCT05010876Written as C1 Inhibitor Human
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain InjuryStatus unknownPhase 2Leiden University Medical CenterNCT04489160Written as C1 Inhibitor, Human
- A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human HyaluronidaseCompletedPhase 2ShireNCT01426763Written as CINRYZE with rHuPH20
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE AdministrationCompletedPhase 2ShireNCT01095497Written as CINRYZE
- A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZECompletedPhase 4ShireNCT00914966Written as C1 inhibitor (human) [C1 INH]
- A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated RejectionCompletedPhase 2ShireNCT01147302Written as C1 Esterase Inhibitor (Human)
- Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema AttacksCompletedPhase 2ShireNCT01756157Written as CINRYZE with rHuPH20
- CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12CompletedPhase 2ShireNCT01095510Written as CINRYZE
- CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%Status unknownPhase 1University of Wisconsin, MadisonNCT02435732Written as CINRYZE
- A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney TransplantTerminatedPhase 3ShireNCT02547220Written as Cinryze®
- A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedPhase 2Pharming Technologies B.V.NCT00851409Written as Recombinant Human C1 Inhibitor
- A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedPhase 2Pharming Technologies B.V.NCT02247739Written as Recombinant human C1 inhibitor
- A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase InhibitorCompletedPhase 1CSL BehringNCT01760343Written as Berinert
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedPhase 2/3Pharming Technologies B.V.NCT00225147Written as Recombinant Human C1 Inhibitor
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedPhase 3Pharming Technologies B.V.NCT00262301Written as recombinant human C1 inhibitor
Codes
What other systems call C1 esterase inhibitor (human) · ClinicalTrials.gg INT004496
- UNII (FDA) 6KIC4BB60GHUMAN C1-ESTERASE INHIBITORConfirmed FDA, Wikidata
- RxNorm 809864Confirmed FDA, Wikidata
- Wikidata Q22075742C1 esterase inhibitor (human)Confirmed FDA, Wikidata
- DrugBank DB06404One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6KIC4BB60G | HUMAN C1-ESTERASE INHIBITOR | Confirmed FDA, Wikidata |
| RxNorm | 809864 | — | Confirmed FDA, Wikidata |
| Wikidata | Q22075742 | C1 esterase inhibitor (human) | Confirmed FDA, Wikidata |
| DrugBank | DB06404 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.